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Summary A panel of 36 cases of preinvasive breast lesions, including 35 cases of ductal carcinoma in situ
(DCIS), has been examined for mutation of TP53, allelic imbalance (Al) on 17pl3, and expression of TP53, in
a number of cases, has been studied using immunohistochemistry. Areas of DCIS, with or without adjacent
invasive or benign cells, have been separately microdissected from paraffin-embedded sections and analysed by
PCR for genetic changes to chromosome l7pl3. TP53 mutations and AI on 17p have been identified in cases
of 'pure' DCIS as well as those with associated invasive carcinoma and, furthermore, have been identified in
well-differentiated lesions as well as poorly differentiated ones.
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The identification of somatic mutations and chromosomal
abnormalities occurring in human breast cancer has resulted
in an increasingly complex picture of breast tumour
development. The difficulty in distinguishing between genetic
alterations, which represent key changes, and those which
have been randomly acquired, has precluded the identifica-
tion of events occurring at specific stages of breast
tumorigenesis. This is largely owing to the failure of previous
studies to focus on different histological subtypes, in
particular early-stage breast tumours. However, in contrast
to colorectal cancer, where there exists a series of well-defined
preinvasive lesions, there is no clear precursor to invasive
breast carcinoma. Furthermore, the classification of many
early-stage breast lesions is often ambiguous.
A number of epidemiological studies on the risk of
developing invasive carcinoma in patients with benign
epithelial hyperplasia (Dupont and Page, 1985; Page et al.,
1985; Tavassoli and Norris, 1990) and with carcinoma in situ
(Rosen et al., 1980; Page et al., 1982) do, however, suggest a
possible continuum from proliferative epithelial changes of
the breast to invasive carcinoma. Ductal carcinoma in situ
(DCIS) is one of the earliest recognisable forms of breast
cancer. Although cytologically the cells are often indistin-
guishable from those of invasive carcinoma, they are confined
within the basement membrane surrounding the duct and
there is no evidence of stromal invasion. As a result of its
frequent finding adjacent to invasive carcinoma, and the
observation that patients with DCIS have a risk ten times
that of the general population of developing invasive breast
tumours, often at the site of the original tumour, DCIS
appears to be a likely candidate for a precursor lesion of
invasive carcinoma (Betsill et al., 1978; Page et al., 1982,
1995). However, despite its high occurrence, the relationship
between DCIS and invasive carcinoma remains unclear. This
is largely due to the heterogeneous nature of the lesions
which constitute DCIS. The disease consists of three main
histological subtypes-comedo, cribriform and micropapil-
lary-which differ in their biological behaviour and prognosis
(Page and Rogers, 1987). In view of this a new classification
has been proposed, dividing cases into well, intermediate and
poor differentiation (Holland et al., 1994). In addition,
studies on the use of local excision as a possible treatment
for DCIS suggest that those patients with the comedo
subtype may be at greater risk of local recurrence (Lagios
et al., 1982). That these tumours may represent a more
aggressive form of DCIS is also suggested by the findings that
alterations to both c-erbB-2 (Gusterson et al., 1988; Van de
Vijver et al., 1988; Barnes et al., 1992a) and TP53 (Varley et
al., 1991; Walker et al., 1991; Poller et al., 1993) have to date
only been identified in the comedo subtype. However, most
of these studies have been carried out on small numbers of
tumours by immunohistochemical analysis, and in the case of
the TP53 gene, there are few reports in which DNA
sequencing was used to confirm the presence of mutations
in those cases of comedo DCIS showing positive staining
(Davidoff et al., 1991; O'Malley et al., 1994). In addition
allelic imbalance (AI), thought to represent inactivation of
tumour-suppressor genes, has been demonstrated at a
number of loci, including TP53, not only in comedo DCIS
but also in cribriform and micropapillary variants of lower
nuclear grade (Radford et al., 1993; Munn et al., 1995, 1996;
Radford et al., 1995; Stratton et al., 1995; Zhuang et al.,
1995).
Here, we report the identification of TP53 mutations in a
panel of 35 cases of DCIS representing all three major
histological subtypes, both with and without associated benign
and invasive disease. In a number of cases we correlate the
results with immunohistochemical staining and Al data, as the
relationship between these and mutation of the TP53 gene in
breast tumours is unclear. Comparison of the patterns of
alterations observed in different stages of tumour from the
same patient allows us to draw important conclusions
regarding the stepwise progression of breast tumours.
Materials and methods
Tumour samples
Nineteen cases of DCIS were obtained from Glenfield
Hospital, Leicester, three of which had an associated area
of frank invasive carcinoma. A further 17 cases were
obtained from Christie Hospital, Manchester, consisting of
13 cases with DCIS and invasive carcinoma, three cases with
an additional benign proliferative component, DCIS and
invasive carcinoma, and one case with a benign component
and invasive carcinoma. A total of 35 cases of DCIS were,
therefore, available for study. For all cases the histological
classification (given in Table I) was confirmed by a
histopathologist (RAW and LM). Nuclear grade of DCIS
was assessed according to Holland et al. (1994). All tumour
samples were formalin fixed and paraffin embedded, and for
the majority of cases a block containing normal breast tissue
was also available.
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Microdissection and DNA extraction
Normal tissue, areas of DCIS from within single ducts, and
benign or invasive carcinoma where present, were micro-
dissected from single dewaxed, haematoxylin-stained 5 or
10 gm sections, and DNA was extracted as previously
described (Munn et al., 1995). In all cases epithelial cells
were microdissected and analysed, and there was minimal
contamination by stromal or inflammatory cells. An average
of three consecutive sections per tumour were analysed.
PCR amplification
PCR reactions were carried out in a volume of 10 gil,
containing 200 giM each dNTP (Promega), 10 pmol of each
primer, 0.5 units Taq DNA polymerase (Promega) and 1 jul
DNA extracted from the microdissected tissue. All reactions
were amplified for 35 cycles, including an initial denaturation
step at 94°C for 4 min, and a final extension at 72'C for
10 min. For the markers described, each cycle consisted of
denaturation at 94°C and extension at 72°C for 1 min each.
Annealing was carried out for 1 min at temperatures ranging
from 56-66°C. However, a number of markers were
amplified using a Touchdown PCR (Don et al., 1991), in
Table I Histology of tumours studied
Case no. Histology Nuclear gradea
Series 1. DCIS
6 Comedo High
15 Cribriform/micropapillary Low
34 Comedo High
56 Comedo/micropapillary Intermediate
75 Comedo High
106 Cribriform Low
144 Comedo/cribriform Intermediate
257 Comedo/cribriform High
1886 Cribriform Low
2281 Comedo High
3410 Comedo High
3800 Comedo/cribriform High
3805 Comedo High
4119 Comedo High
4736 Comedo Intermediate
4753 Comedo High
Series 2. DCIS and invasive carcinoma
452 Micropapillary + ID Low (II)
458 Cribriform +ID High (III)
593 Cribriform +ID Low (I)
982 Cribriform +ID Intermediate (II)
1141 Cribriform +ID ND (III)
1565 Florid hyperplasia, comedo+ID Intermediate (II)
2753 Cribriform/solid + ID Low (II)
2822 Cribriform +ID Low (II)
2931 Micropapillary + ID ND (III)
2939 Cribriform +ID Intermediate (II)
2996 Sclerosing adenosis, comedo +ID High (III)
3041 Cribriform+tubular carcinoma Low (I)
4410 Comedo +ID High (III)
4617 Comedo/micropapillary +ID High (III)
4681 Cribriform/papillary +ID Intermediate (II)
5170 Comedo +ID High (III)
6045b Papilloma, comedo +ID Intermediate (II)
6256 Cribriform +ID Low (II)
6384 Comedo + ID Intermediate (II)
6457 Fibroadenosis, comedo +ID High (III)
Series 1 comprises those samples in which DCIS is present alone,
series 2 in which there is an additional benign or invasive component.
aNuclear grade of DCIS was classified according to Holland et al.
(1994) as low, intermediate or high. For samples in series 2, the grade
of the invasive component is given in parentheses where known, and
was assessed according to Elston and Ellis (1991). bSample 6045 was
classified as comedo DCIS adjacent to invasive, with papilloma
present. Onthesectionweobtained, therewasnoDCIS, therefore only
the papilloma and invasive cell were studied. ND, not determined.
which two cycles were performed at an initial annealing
temperature of 700C. The annealing temperature was then
reduced by increments of 20C, and two cycles were carried
out at each temperature until 500C was reached, at which 20
cycles were carried out.
Single-strand conformation polymorphism analysis
Tumour DNA was screened for mutations in exons 4-9 of
the TP53 gene using single-strand conformation polymorph-
ism (SSCP) (Orita et al., 1989). For exon 4 and 9 the
following primers were used:
Exon 4
Exon 9
5'-TCTGGTAAGGACAAGGGTT-3'
5'-GGCAACTGACCGTGCAAG-3'
5'-ACTAAGCGAGGTAAGCAA-3'
5'-CTTTCCACTTGATAAGAGG-3'
For exons 5-8 two sets of primers were used, as it is
thought that the position of a mutation within a fragment
may influence its detection (Sheffield et al., 1993). The
sequences of these primers have previously been described
(Varley et al., 1991). The majority of the primers used
amplified products of between 100 and 250 base pairs, as
this size is thought to be optimal for the detection of
mutations by SSCP. For larger sequences products were
digested by restriction endonucleases before gel electrophor-
esis. Products were radiolabelled by reducing the concentra-
tion of cold dCTP in the reaction to 10,M and adding
1 1Ci [oc-32P]dCTP. Before electrophoresis, 2 tl product were
diluted with 6 MI 10 mM EDTA/0.1% sodium dodecyl
sulphate (SDS) and 6 pl loading dye (95% formamide,
20 mM EDTA, 0.05% bromophenol blue, 0.05% xylene
cyanol). Samples were heat denatured for 2 min and
immediately loaded on a non-denaturing polyacrylamide
gel run in 0.5 x Tris-borate buffer. Products were analysed
normally on several types of gel: 0.5 x MDE HydroLink
(AT Biochemicals) or 8% polyacrylamide, containing 5 or
10% glycerol. Gels were either run at 15W for 8-1Oh at
room temperature with the use of a cooling fan, or at 4°C.
After electrophoresis, gels were transferred to 3MM paper,
dried at 80°C under vacuum and exposed to radiographic
film.
DNA sequencing
Normal and tumour DNA were amplified for 35 cycles using
the outer most set of primers. A secondary reaction in a
volume of 30 ,ul, containing 0.5 jul of first round product and
5 pmol of each primer, was then amplified for twenty cycles.
Products were analysed on 2% agarose gels and the fragment
subsequently purified using Magic DNA Clean-up Columns
(Promega). Double-stranded PCR products were sequenced
using a variation of the dideoxy chain termination method
(Winship, 1989). Products were analysed on 6% denaturing
polyacrylamide gels.
Immunohistochemistry
Paraffin-embedded tissue sections of 5 gM thickness were
stained using both DO-I (a gift from D Lane), a murine
monoclonal antibody which recognises a denaturation-
resistant epitope at amino acids 20-25 of human p53, and
CM-I (Novocastra Labs), a rabbit polyclonal serum raised
against recombinant human p53 protein (Midgley et al., 1992;
Vojtesek et al., 1992). Sections were incubated with primary
antibody (undiluted and 1:800 dilutions respectively) over-
night at 4°C. For both antibodies the avidin-biotin -
peroxidase complex was developed using 3,3-diaminobenzi-
dine as the chromogen. Only nuclear staining was assessed.
Tumours were subdivided into those with >50% cells
reactive; 20-50% positive cells; patchy staining in some
ducts <20%; scant positive cells and negative. Only samples
from series 1 were analysed by immunohistochemistry.TP53 mutation and Al on 17p in DCIS
KE Munn et al
1580
Detection of allelic imbalance
Four microsatellite DNA length polymorphisms on chromo-
some 17p were used to detect Al: D17S926 (Gyapay et al.,
1994), TP53(AAAAT)n (Futreal et al., 1992), TP53(CA)n
(Jones and Nakamura, 1992) and D17S513 (Oliphant et al.,
1991). The primer sequences used to amplify the pentanucleo-
tide and dinucleotide repeats within TP53 differed from those
used in the original publications.
TP53(AAAAT)n 5'-AAACAGCTCCTTTAATGGCAG-3'
5'-ATCATTTGAATCCGGGAGGA-3'
TP53(CA)n 5,-CCTGAGGATACTATTCAGCC-3'
5'-CCCACAGAGCGAGACTGTCT-3'
In addition, four polymorphisms were used to control for Al
on the long arm of chromosome 17, as previously described
(Munn et al., 1996). Products were radiolabelled by
incorporation of [oC-32P]dCTP, and analysed on 6% denatur-
ing gels. For analysis ofthe BstUl restriction fragment length
polymorphism (RFLP) in exon 4 (Ara et al., 1991), normal
and tumour DNA were amplified in a 30 ,ul volume, and
10 jul of product was subsequently digested. Products were
analysed on 3% agarose gels. Al was determined by eye in
heterozygous patients by comparing the ratio of the two
alleles in the tumour and normal samples. A difference in
intensity between the two alleles in the tumour, which by eye
appeared to be at least 2-fold, was taken to represent Al. For
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microsatellite repeat polymorphisms a number of cases were
also confirmed by the use of a phosphorimager (Molecular
Dynamics).
Results
Mutations in the TP53 gene
Exons 4-9 of the TP53 gene were amplified individually
from normal tissue and several areas of tumour from all 36
cases, and subsequently analysed by SSCP. This region
encodes the most highly conserved domains of the protein,
and is the site of the majority of mutations that have been
identified in human tumours. Seven possible somatic
mutations were identified in exons 5-8 by the presence of
additional bands, or bands of aberrant mobility in the
tumour sample (Figure la). For all positive samples, the
SSCP analysis was repeated from reamplified material to
ensure that the altered pattern of bands was not caused by
extraneous DNA, or by the misincorporation of a base in the
initial cycles of the PCR amplification. In all cases the results
were reproducible. In five cases the mutations were confirmed
by DNA sequencing of double-stranded PCR products
(Table II, Figure lb). Four of the mutations were base
substitutions, while the remaining mutation was a frameshift
due to a single base deletion. Three of these cases (6, 2281
and 3805) were comedo DCIS of poor differentiation.
However, in one case, 106, the mutation was present in a
well-differentiated lesion. For cases 106, 2281 and 3805 more
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Figure 1 (a), Detection of TP53 mutation by SSCP analysis of 32P-labelled PCR products. Bands of aberrant mobility in samples
106 and 2281, suggestive of a mutation, are indicated by arrows. The examples shown were run at room temperature on a 5%
polyacrylamide gel containing 10% glycerol, and on a 0.5 x MDE polyacrylamide gel containing 5% glycerol (exons 5 and 7
respectively). In this autoradiographic exposure no signal can be seen from sample 1886Cr. (b), Mutations detected by SSCP
analysis were confirmed by sequencing of double-stranded PCR products; sequence changes are indicated. In case 2281 the
mutation is shown on the complementary strand. In case 458 no mutation was detected in the DCIS component; however, the
mutation in the invasive sample appears to be homo- or hemizygous. In contrast, the presence of the wild-type sequence, of
roughly equal intensity, in case 2281 suggests that the mutation is heterozygous. N, normal; C, comedo DCIS; Cr, cribriform
DCIS; I, invasive tumour.TP53 mutation and Al on 17p in DCIS
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Table II TP53 mutations identified in this study and the corresponding results of immunohistochemical staining and Al studies
Case Histology Grade Exon Codon Base change Amino acid change IHCa AIb
106 Cribriform Low 5 153 CCC-CCA Pro-Pro +/- +
6 Comedo High 6 202 CGT-)CAT Arg-+His - +
458 Invasive III 6 215 AGT-+GGT Ser-iGly ND
2281 Comedo High 7 237 ATG--ATC Met-Ile + +
3805 Comedo High 8 304 Del T Terminates at 344 + + +
aIHC, immunohistochemistry; + +, strong nuclear staining in at least 50% ofthe tumour cells; +/-, heterogeneous staining; ND, not done.
bAl, allelic imbalance determined at the TP53 locus using three intragenic polymorphisms.
Table III p53 immunohistochemical staining data for 15 cases of
DCIS without associated invasive disease
Case Histology Grade p53 staininga
6 Comedo High
15 Cribriform/micropapillary Low
56 Comedo/micropapillary Intermediate -/+
75 Comedo High + +
106 Cribriform Low +/_b
144 Comedo/cribriform High +
257 Comedo/cribriform High + +
1886 Cribriform High
2281 Comedo High + +
3410 Comedo High
3800 Comedo/cribriform High
3805 Comedo High + +
4119 Comedo High
4736 Comedo/micropapillary Intermediate
4753 Comedo High -/ +
a+, nuclear staining in more than 50% of the tumour cells; +,
nuclear staining in 20-50% ofthe tumour cells; +4-, patchy pattern
ofpositive staining;-/+, scant positive staining. Faint cytoplasmic
staining with CM-1.
than one DCIS-containing duct from the same quadrant was
analysed and the mutation was found to be present in some
ducts but not others, indicating that the tumour is
heterogeneous. The remaining case, 458, showed no evidence
of a mutation in the two areas of cribriform DCIS studied,
but did contain a mutation in the infiltrating carcinoma. In
cases 6, 458 and 3805, the DNA sequence of the tumour
showed only mutant sequence, indicating that loss of the
remaining wild-type allele had occurred. Two cases, one
consisting of DCIS and the other of cribriform DCIS with
infiltrating carcinoma, gave positive results in the SSCP
analysis of exon 7 which could not be confirmed by DNA
sequencing (cases 3800 and 2753). In addition, eight cases,
which appeared negative by SSCP (of which four were
invasive tumours), including one which showed positive
staining with p53 antibodies (see below), were also
sequenced and found not to contain any mutations in the
region analysed.
p53 expression
Fifteen cases of pure DCIS from series 1 were stained with
the antibodies DO-1 and CM-1 (see Table III). In all areas of
normal tissue negative staining patterns were observed. Of
those eight cases (53%), which showed positive staining, the
patterns of staining could be divided into four classes. The
majority of those that were positive showed moderate to
strong nuclear staining, which was present in at least 50% of
the tumour cells (Figure 2). This pattern was observed
predominantly in comedo DCIS, but was also seen in a
poorly differentiated area of cribriform DCIS in case 257. In
a further case showing positive staining, the proportion of
positive cells was as low as 30%. In addition, three cases
displayed a heterogeneous pattern of staining in which
tumour cells in some parts of the tumour showed positive
nuclear staining, while others were negative. One cribriform
... _ r -- -
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Figure 2 Immunohistochemical staining for TP53 expression
using polyclonal antiserum CM-1. (a), Case 106 shows strong
nuclear staining in scattered cells in an area of cribriform DCIS.
Case 2281 (b), in which a mutation in exon 7 of the TP53 gene
was identified, shows strong nuclear staining in an area ofcomedo
DCIS.
case also showed some cytoplasmic staining with CM-1;
however, cross-reactivity of this antibody has been reported
previously (Cornelis et al., 1994). Of the cases stained, four
contained a TP53 mutation. One case (6), which contained a
missense mutation, had no evidence of staining. Case 2281,
which had a missense mutation, and case 3805, which had a
frameshift resulting in deletion of the last 50 amino acids,
both showed strong nuclear staining (Figure 2b). However,
case 106, which had silent mutation, also showed positive
staining, although the pattern was patchy (Figure 2a). In
addition, for five cases in which no mutation was identified
by SSCP, one of which was also sequenced, positive staining
was observed.TP53 mutation and Al on 17p in DCIS
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Series 1
Case 6 15 34 56 75 106 144 257 1886 2281 3410 3800 3805 4119 4736 4753
Locus C1 C2 MP C MP C1 C2 Crl Cr2 C1 C2 C Cr C C Cr | C C C1 C2|C1 C2
D17S926@ - 0 0 - 0 0 0
D17S513 O000 0 0 0 0 0 0 0
TP53t * o Oo*ooo Oo - * * * _ o °0 = - - o _ °_
Series 2
Case 452 458 593 982 1141 1565 2753 2822 2931 2939 2996 3041 4410 4617 4681 5170 6045 6256 6384 6457
Locus MP Cr I Cr Cr I Cr BCIC21 Cr Cr MP Cr BC Cr C MP PCrI C B Cr C B C
D17S926 - *_ *- 0001 0 l |_ 0 0 0| | |
D17S513 * * O_0 00000 _ - | 0l00 0 00 0*0 - 0 0 - 000 0
Tp53t 0* 00 00 00 0 O 0 0000 0* 0 0 o - - l0 0o0000 - - 000l 0 0l - @ 01 - 10001
Figure 3 Results of allelic imbalance (Al) studies at chromosome 17pl3. (0), informative and both alleles retained; (0),
informative and showing Al; (-), uninformative; no symbol, not tested owing to lack of material or sample consistently failing to
amplify. t Al at TP53 was determined using three intragenic polymorphisms in order to maximise the number ofinformative cases.
Cases in bold contain a TP53 mutation. C, comedo DCIS; Cr, cribriform DCIS; MP, micropapillary DCIS; P, papillary DCIS; B,
benign; I, invasive. Where multiple ducts have been sampled from the same patient they are indicated by Crl, Cr2, etc.
AI at chromosome 17p.13
Al at TP53 was determined by the use of three intragenic
polymorphisms. In order to distinguish between events
occurring at the TP53 locus from those involving the
telomeric region of 17p, two distal markers, D17S513 and
D17S926, were used. Several markers on 17q were also used,
as previously described (Munn et al., 1996), and serve as a
control for possible loss of a whole copy of chromosome 17.
As a result oflimiting amounts of DNA from some lesions, it
was not possible to test all cases with every marker. In
addition, some cases consistently failed to amplify with some
sets of primers. All cases were, however, informative for at
least one marker on 17p and, in 21 of the 35 DCIS cases
(60%), Al on 17p was observed in the DCIS component
(Figure 3). These cases included five well-differentiated,
cribriform or micropapillary lesions. Eight of these cases
showed Al at all informative markers studied on both 17p
and 17q, suggesting possible loss of a copy of the
chromosome, while a further two cases showed possible loss
of a copy of the short arm. Of 28 cases of DCIS that were
informative at the TP53 locus, 19 cases (68%) of DCIS
showed Al. However, only ten ofthese cases showed retention
of either of the distal markers used. As there is evidence for a
second tumour-suppressor gene, which maps somewhere
between these two markers, then the percentage of DCIS
cases showing Al, which appears to target TP53, is 36%. A
single case of comedo DCIS, 3410, was found to show AI
independent from TP53 at D17S926, implicating the more
distal gene in early breast tumours. Of those cases known to
contain TP53 point mutations, three were predicted to show
Al based on the sequencing data. Both cases 6 and 3805
showed clear loss of an allele. However, case 458 showed
retention of heterozygosity at TP53. This discordancy in the
results can be explained if a deletion of the wild-type
homologue or intragenic recombination had occurred
between the (AAAAT)n repeat in intron 1 and the site of the
mutation in exon 6. Both cases 2281 and 106 had sequences
suggesting that the mutation was heterozygous. The AI data
confirmed this for case 2281, but case 106 showed Al
suggesting that the residual wild-type signal in the sequence
was due to normal contamination. Ofthose cases studied with
an associated area of invasive carcinoma, 12 showed Al in
either component and, in ten ofthese cases, there was the same
pattern ofallele loss in both. The remaining two cases showed
Al in the invasive tumour but not in the DCIS (4617 and 4681,
Figure 4a). Both these samples showed loss at other loci in the
a b
4681
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Figure 4 Allelic imbalance (AI) at the (AAAT)n microsatellite
repeat polymorphism in the TP53 gene. (a), Al in the invasive
component of case 4681, but not in the DCIS. (b), Al in an area
of comedo DCIS from patient 1565. In contrast, a second area of
comedo DCIS present on the same section showed retention of
both alleles. N, normal; C, comedo DCIS; Cr, cribriform DCIS; I,
invasive tumour.
DCIS components. Case 4617 showed loss of 17q markers
(Munn et al., 1996) and the cribriform component of 4681
showed loss of chromosome 1 markers (Munn et al., 1995).
However, the papillary component of 4681 showed no loss at
any of the loci we have studied. For four cases, associated
benign proliferative disease was also studied. In two of these
cases, no Al was observed, even though there was Al in the
DCIS and invasive carcinoma from the same patient.
However, in case 6457 Al was observed in an area of
fibroadenosis. Loss of the same allele was demonstrated in
both the DCIS and invasive components. There was an area of
atypical ductal hyperplasia described in the original report on
6457, but we did not receive this material and, therefore, could
not analyse it. In eight cases DCIS from within separate ducts
on the same section were analysed. Consistent with the results
from the mutation analysis, four of these showed a different
pattern of Al in each component (Figure 4b), which in one
case, 106, involved the loss of different alleles.
Discussion
To date, there have been few reports documenting the
identification of genetic alterations in DCIS, as the small size
of the lesions restricts analysis to paraffin-embedded material.
However, the use of PCR to analyse small microsatelliteTP53 mutation and Al on 17p in DCIS
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repeat polymorphisms has resulted in a number of reports of
Al at several regions of the genome, thought to harbour
tumour-suppressor genes. Here, we have used a combination
of tissue microdissection and PCR to look for TP53
mutations and Al on chromosome 17pl3. In contrast to
many of the previously published studies, we have used
microdissection to isolate small numbers of tumour cells from
within single DCIS-containing ducts rather than from larger
areas of DCIS, which may consist of several ducts. This
overcomes problems of stromal contamination and tumour
heterogeneity, which may mask Al.
The identification of TP53 mutations and Al at l7pl3 in
cases of DCIS, both with and without associated invasive
carcinoma, suggests that these are important changes in the
early stages of breast tumorigenesis. Previous estimates of the
frequency of TP53 mutations in invasive carcinomas, based
on immunohistochemistry, have ranged from 25-60% (for
review see Eeles et al., 1994). Molecular analysis has, in
contrast, revealed a frequency of only 13-30% (Prosser et
al., 1990; Varley et al., 1991; Cornelis et al., 1994). In DCIS
the reported frequency of p53 overexpression is much lower
at around 10-25% (Bartek et al., 1990; Poller et al., 1993),
although Bobrow et al. (1995) reported 50%, and there are
only two reported cases in which TP53 mutations were
identified in DCIS by sequencing (Davidoff et al., 1991;
O'Malley et al., 1994). Using a combination of SSCP and
DNA sequence analysis of small foci of tumour cells from
DCIS, we have identified TP53 mutations in four cases
(11%). Those three cases in which the mutation was missense
or led to a truncated protein, were all comedo DCIS of poor
differentiation. The fourth case, a well-differentiated cribri-
form lesion, contained a silent mutation. This case has
previously been reported to show AI on chromosome 1
(Munn et al., 1995). Therefore, selection for a mutation in the
gene, which is the target of Al on chromosome 1, may
account for the maintenance of this TP53 mutation in the
tumour. In 53% of those cases which were stained with anti-
p53 antibodies, positive staining was observed. This
frequency is significantly higher than seen in previous
studies, possibly because of our small sample size. How-
ever, the majority of these cases did not appear to have TP53
mutations. A likely explanation for this may be the failure of
SSCP to identify all mutations, although in previous studies
of known TP53 mutants, its sensitivity is estimated to be
around 90% (Moyret et al., 1994). Also, the possibility of
mutations in the regulatory region of the gene or in the
remainder of the coding region cannot be eliminated. In
addition, some of these cases showed staining in a small
proportion of the cells in the tumour, or showed a
heterogeneous pattern of staining. In such cases the presence
of a mutation in a wild-type background may be difficult to
detect using PCR-based techniques. Furthermore, it has been
reported that overexpression of TP53 protein does occur in
the absence of mutation (Barnes et al., 1992b). This may be a
result of the overexpression of a protein which binds p53 and
stabilises it, e.g. MDM2, or it may be caused by the presence
of DNA damage in the tumour cell. Whatever the mechanism
of the observed overexpression, these results are interesting in
that there are no previous reports of positive staining in
cribriform DCIS, and there is only one reported case of
micropapillary DCIS that shows overexpression of TP53
(Thor et al., 1992).
In contrast, the observed frequency of AI on chromosome
17p in DCIS is similar to that reported for invasive tumours
(Varley et al., 1991; Andersen et al., 1992; Cornelis et al.,
1994). In a number of cases the TP53 gene appears to be the
target of Al. However, few of these cases were found to
contain a TP53 mutation. The loss of one copy of the TP53
gene may, therefore, confer some growth advantage on the
cell, possibly because the reduced dosage of wild-type p53
protein increases the tumour's chances of accumulating
further mutations. In a larger number of cases there was
also Al distal to TPS3. There is both molecular and
functional evidence for a tumour-suppressor gene distinct
from TP53 near the telomere of chromosome 17p (Stack et
al., 1995; Theile et al., 1995). Therefore, it is unclear in these
cases which gene was the target of Al; however, one case did
show Al at 17pl3.3 independent from TP53, suggesting that
this gene may have a role in the early stages of breast
tumorigenesis. A number of these cases also showed Al at all
informative markers studied on 17q, and in the majority the
patterns consisted of clear allele loss rather than allele
imbalance, suggesting possibly that a copy of the whole
chromosome had been lost. Obviously, using PCR-based
techniques it cannot easily be determined whether this has
been followed by duplication of the remaining homologue,
but previous studies, using interphase cytogenetics, have
reported polysomy for chromosome 17 in DCIS (Murphy et
al., 1995).
From these data, and much of that which has previously
been documented, it is evident that a large number of the
genetic alterations known to occur in invasive breast tumours
are already present in DCIS. This is clearly not only the case
for high-grade comedo lesions. Here we have demonstrated
AI on chromosome 17p in a number of well-differentiated
cribriform and micropapillary lesions, both with and without
associated invasive disease. Unfortunately, we failed to
identify common TP53 mutations in DCIS and invasive
tumourJrom the same patient, which would have provided
strong evidence for the preinvasive nature of DCIS. The
patterns of Al in a number of cases do, however, support
this. We have also identified one case of fibroadenosis, which
shows AI and displays the same pattern of allele loss in DCIS
and invasive components from the same patient (6457). The
relationship between benign, in situ and invasive disease is
not always likely to be as simple as in 6457. Although DCIS
has previously been reported to be clonal in origin (Noguchi
et al., 1994), there is clearly heterogeneity within the DCIS
component, and we and others have previously reported cases
in which there was loss in the benign or in situ component
and not in the invasive tumour (Munn et al., 1995, 1996;
Stratton et al., 1995). It is likely, therefore, that DCIS exists
as divergent populations, only some ofwhich may acquire the
changes necessary for them to become invasive carcinoma.
The application of this kind of approach to lesions, such as
atypical ductal hyperplasia, which are thought to be
borderline between hyperplasia and neoplasia, will hopefully
provide a clearer picture of the pathway of tumour
development.
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